Henri Fernandez

Venture capital for tomorrow’s greatest healthcare companies

The GSB Impact Fund is an evergreen fund that invests in early-stage for-profit ventures seeking both financial and social and environmental returns.

Venture capital for tomorrow’s greatest healthcare companies

The 26 Fund is a seed fund that invests in businesses founded by entrepreneurs of the Stanford Graduate School of Business Class of 2026.

The GSB Impact Fund is an evergreen fund that invests in early-stage for-profit ventures seeking both financial and social and environmental returns.

Shine Small is a 501(c)(3) non-profit that provides minority-owned small businesses in Brooklyn, Bronx, Queens, and Staten Island crowdfunding and volunteer mentorship advice from young professionals in finance and marketing.

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.